| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
243.96(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
180,030 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,509,387 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
9 |
21 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ottinger Bradley |
General Counsel and CCO |
• – – |
2022-03-16 |
4 |
D |
$7.97 |
$5,165 |
D/D |
(648) |
3,073 |
|
- |
|
| Ottinger Bradley |
General Counsel and CCO |
• – – |
2022-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,563 |
3,721 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2022-03-16 |
4 |
D |
$7.97 |
$19,503 |
D/D |
(2,447) |
21,769 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
24,216 |
|
- |
|
| Devinney Erick Wayne |
VP Peripheral Nerve Science |
• – – |
2022-03-16 |
4 |
D |
$7.97 |
$11,931 |
D/D |
(1,497) |
92,578 |
|
- |
|
| Devinney Erick Wayne |
VP Peripheral Nerve Science |
• – – |
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
94,075 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2022-03-16 |
4 |
D |
$7.97 |
$12,051 |
D/D |
(1,512) |
61,941 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
63,453 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,950 |
966,333 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2022-02-22 |
4 |
OE |
$5.09 |
$78,150 |
D/D |
15,000 |
57,453 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,978 |
940,383 |
|
- |
|
| Friedman Mark Louis |
VP Regulatory Affairs & Policy |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$3,006 |
D/D |
(357) |
19,845 |
|
- |
|
| Friedman Mark Louis |
VP Regulatory Affairs & Policy |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,181 |
20,202 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$1,726 |
D/D |
(205) |
42,453 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
675 |
42,658 |
|
- |
|
| Sandberg Eric |
Chief Commercial Officer |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$6,416 |
D/D |
(762) |
8,310 |
|
- |
|
| Sandberg Eric |
Chief Commercial Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,531 |
9,072 |
|
- |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$3,368 |
D/D |
(400) |
6,656 |
|
- |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,325 |
7,056 |
|
- |
|
| Mariani Peter J |
EVP & Chief Financial Officer |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$7,999 |
D/D |
(950) |
26,353 |
|
- |
|
| Mariani Peter J |
EVP & Chief Financial Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,157 |
27,303 |
|
- |
|
| Scopelianos Angelo |
Chief R&D Officer |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$3,368 |
D/D |
(400) |
11,950 |
|
- |
|
| Scopelianos Angelo |
Chief R&D Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,325 |
12,350 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2022-02-15 |
4 |
D |
$8.42 |
$3,764 |
D/D |
(447) |
15,716 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,325 |
16,163 |
|
- |
|
470 Records found
|
|
Page 6 of 19 |
|
|
0.04 (0.69%) 
